Non-small cell lung cancer

News

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.

News

Summit shrugs off survival miss with its VEGF bispecific

Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.

News

MSD and Daiichi Sankyo pull HER3-DXd's FDA filing

MSD and Daiichi Sankyo suffer another setback with their HER3 programme ahead of a crucial data readout at ASCO.

News

AbbVie bags first approval for cancer ADC Emrelis

AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.

News

Dr Yu Xia, founder, chairwoman, president and chief executive of Akeso

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

News

CRUK scientists find new tool to test lung cancer therapies

Researchers in the UK have developed a lung cancer cell line that they believe could be an important new tool for the discovery of new therapies.

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Summit shrugs off survival miss with its VEGF bispecific

MSD and Daiichi Sankyo pull HER3-DXd's FDA filing

AbbVie bags first approval for cancer ADC Emrelis

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

CRUK scientists find new tool to test lung cancer therapies

Scribe Therapeutics joins the IPO queue

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks